Ocugen, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2022; filed May 6, 2022. Ocugen is a clinical-stage biotechnology company with no products approved for commercial sale and no significant revenue to date. Its principal programs are COVAXIN, the OCU400/OCU410 modifier gene therapy platform, and OCU200.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | Not significant | Not significant | — |
| Research and development expense | $7.9 million | $2.9 million | +$5.0 million |
| General and administrative expense | $10.1 million | $4.2 million | +$5.9 million |
| Total operating expenses | $18.0 million | $7.1 million | +$11.0 million |
| Net loss | $18.0 million | $7.1 million | +$10.9 million loss |
| Net loss per share | $0.09 | $0.04 | Higher loss per share |
| Net cash used in operating activities | $15.1 million | $5.3 million | +$9.8 million use |
- The filing does not provide a meaningful revenue or operating margin because the company has not generated significant product revenue and remains loss-making.
- Cash, cash equivalents, and restricted cash were $129.9 million at March 31, 2022, compared with $95.1 million at December 31, 2021.
- February 2022 equity financing generated approximately $49.8 million of net proceeds from the sale of 16.0 million common shares at $3.13 per share.
- Total liabilities were $10.6 million, including $1.7 million of net long-term EB-5 debt and $1.4 million of operating lease liabilities.
- Accumulated deficit was $149.7 million; stockholders’ equity was $131.1 million.
- Stock-based compensation expense increased to $3.3 million from $0.8 million in the prior-year quarter.
Material changes versus the prior comparable period
- Research and development expense rose primarily from higher employee costs, COVAXIN development, regulatory and manufacturing activities, stock-based compensation, and OCU200 preclinical work.
- General and administrative expense increased due to higher professional fees, employee costs, stock-based compensation, and COVAXIN pre-commercialization activities. The increase was partly offset by lower costs related to the 2021 authorized-share increase process.
- Operating cash burn increased substantially as development, staffing, professional-fee, and commercialization expenses expanded.
- Financing cash inflows increased to $50.1 million from $26.3 million, primarily because of the February 2022 public offering.
- Common shares outstanding increased to approximately 215.6 million at March 31, 2022 from approximately 199.4 million at December 31, 2021.
Business developments, outlook, and risks
- COVAXIN: Ocugen is pursuing a U.S. Biologics License Application pathway for adults rather than an Emergency Use Authorization. Its Phase 2/3 immuno-bridging and broadening trial was subject to a temporary dosing pause and FDA clinical hold after WHO identified Good Manufacturing Practice deficiencies at Bharat Biotech’s facility. The filing states that the company must address FDA concerns before dosing can begin and before related safety trials can proceed.
- The FDA declined the company’s pediatric COVAXIN EUA request in March 2022. Ocugen plans to evaluate an alternative U.S. pediatric regulatory pathway.
- Health Canada issued a Notice of Deficiency requesting additional clinical, preclinical, and chemistry, manufacturing, and controls information. Ocugen’s responses remained under review.
- Mexico rights were added through an April 2022 amendment. Adult emergency use approval in Mexico remained active, while pediatric use was under COFEPRIS review. Ocugen had limited experience commercializing products in Mexico.
- Technology transfer and commercial manufacturing preparations with Jubilant HollisterStier were in progress. The company committed to purchase approximately $14.3 million of COVAXIN drug product components to support the transfer.
- OCU400: The first patient was dosed in March 2022 in a Phase 1/2 trial for certain inherited retinal degenerations. The company continued enrollment; the filing reports that an independent Data and Safety Monitoring Board later recommended continued enrollment at the target dose level.
- OCU410 and OCU200: OCU410 remained in pre-IND studies for dry age-related macular degeneration. OCU200 remained in pre-IND and manufacturing-process development for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.
- Management states that existing cash will not meet capital requirements over the next 12 months. The company expects to require significant additional financing through equity, debt, collaborations, grants, licensing, asset sales, or other sources.
- The financial statements disclose substantial doubt about the company’s ability to continue as a going concern within one year after issuance. Failure to obtain financing could require delaying, reducing, or eliminating programs, pursuing strategic alternatives, or ceasing operations.
- Two consolidated securities class actions and consolidated stockholder derivative litigation were pending. Management believes the claims are without merit; no loss was accrued because a probable and reasonably estimable loss could not be established.
- Key risks include clinical and regulatory delays, COVAXIN manufacturing and supply deficiencies, reliance on Bharat Biotech and other third parties, uncertain market demand, continued operating losses, potential equity dilution, COVID-19 and geopolitical disruptions, and intellectual-property and litigation exposure.
Important facts for investors to verify
- Current status of the FDA clinical hold on the adult COVAXIN trial and the requirements for lifting it.
- Whether Bharat Biotech and its manufacturing facilities have satisfactorily addressed WHO and FDA concerns.
- Regulatory outcomes for COVAXIN in the United States, Canada, and Mexico, including the pediatric pathway and Mexican commercialization.
- Timing, cost, and terms of additional financing, and the resulting dilution or debt burden.
- Actual cash runway relative to management’s stated need for funding within the next 12 months.
- Progress, safety, and enrollment results for the OCU400 clinical trial and development timelines for OCU410 and OCU200.
- Potential obligations under the COVAXIN supply commitment, leases, consulting arrangements, and the Bharat Biotech agreement, including the company’s 45% share of any defined operating profits.
- Developments, potential damages, and insurance coverage related to the pending securities and derivative lawsuits.